[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-lymphocytic-leukaemia-cll\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-lymphocytic-leukaemia-cll":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100574680","phase-iii-open-label-study-evaluating-the-safety-and-efficacy-of-concomitant-administration-of-anti-cd19-car-t-cell-therapy-and-lenalidomide-in-refractoryrelapsed-chronic-lymphocytic-leukemia-patients-100574680",false,"NCT06762431","Phase I\u002FII Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory\u002FRelapsed Chronic Lymphocytic Leukemia Patients.","VTB-CLL002","Inclusion Criteria:\n\n* Documented CD19+ CLL or SLL\n* Patients must have failed at least 1 prior regimen\n* Patients must be currently receiving ibrutinib for at least 3 months prior to enrollment in the study and:\n* Not experiencing any ≥ grade 2 non-hematologic ibrutinib-related toxicity\n* ECOG Performance status 0 or 1\n* 18 years of age and older\n* Adequate organ system function including:\n\nCreatinine \\\u003C 1.6 mg\u002Fdl ALT\u002FAST \\\u003C 3x upper limit of normal Total Bilirubin \\\u003C2.0 mg\u002Fdl with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is ≥ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN.\n\n* Have no active GVHD and require no immunosuppression\n* Are more than 6 months from transplant\n* No contraindications for leukapheresis\n* Left Ventricular Ejection fraction \\>50%\n* Gives informed consent\n\nExclusion Criteria:\n\n* CLL patients with known or suspected transformed disease (i.e. Richter's transformation).\n* Pregnant or lactating women.\n* Uncontrolled active infection.\n* Active hepatitis B or hepatitis C infection.\n* Concurrent use of systemic steroids or chronic use of immunosuppressant medications.\n* Any uncontrolled active medical disorder\n* HIV infection.\n* Patients with active CNS involvement with malignancy.\n* Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n* Subjects with clinically apparent arrhythmia or arrhythmias who are not stable","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a Phase I\u002FII interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed\u002Frefractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.",[27,28],"Chronic Lymphocytic Leukaemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[30,31,32],"anti-CD19 CAR T-cells","Lenalidomide","Ibrutinib","RECRUITING","2026-08-12",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":37},"2024-05-14",{"date":41,"type":20},"2026-08-31",{"name":43,"class":44},"Vitebsk Regional Clinical Cancer Centre","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100579252","developing-a-patient-reported-outcome-pro-screening-measure-for-infections-and-measuring-quality-of-life-in-hematological-patients-with-secondary-immunodeficiency-sid-across-the-treatment-trajectory---the-pro-sid-project-100579252","NCT06821880","Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project","PRO-SID","Inclusion Criteria:\n\n* Adult patient (\\>=18 years of age)\n* Access to an internet device (e.g., personal computer or tablet to use a web-based platform, or smartphone where the study app can be installed - all common iOS and Android systems)\n* German-speaking\n* Diagnosis of multiple myeloma or chronic lymphocytic leukemia\n* Secondary immunodeficiency (defined as: recurrent infections, infections requiring inpatient treatment, hypogammaglobulinemia, neutropenia and\u002For lymphopenia on differential blood cell counts, deficit in lymphocyte subsets as assessed by flow cytometry)",{"count":54,"type":20},120,"OBSERVATIONAL","The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections. The study focuses on adults diagnosed with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who are at increased risk of infections due to SID.\n\nThe main questions it aims to answer are:\n\n1. Can a newly developed PRO screening tool for infection-related symptoms reliably detect infections in patients with SID?\n2. How does the health-related quality of life change over the treatment course\n\nParticipants will:\n\n* Complete daily electronic PRO questionnaires (ePRO) to monitor infection-related symptoms\n* Complete ePRO health-related quality of life questionnaires every 1.5 months\n* Participate in study visits every three months to ensure documentation of clinical data",[27,58,59],"Multiple Myeloma (MM)","Secondary Immunodeficiency (SID)",[27,61,62,63,64,65,66],"multiple myeloma (MM)","Secondary immunodeficiency (SID)","Infection-related symptoms","Infections","PRO measure","Patient-reported outcomes","2025-02-11",{"date":69,"type":37},"2025-02-12",{"date":71,"type":37},"2025-02-03",{"date":73,"type":20},"2026-07",{"name":75,"class":44},"Medical University Innsbruck",5]